Biotronik today announced a strategic shift that includes the divestiture of its Vascular Intervention (VI) business to Teleflex.
This deal comes as part of a major change at Teleflex, too, as the company today announced plans to separate into two separate businesses.
Biotronik said its shift aims to strengthen its leadership in active implantable devices and digital healthcare. The company wants to leverage future technologies, including AI, remote patient monitoring and connected healthcare platforms.
As part of the shift, the company agreed to divest the VI division to Teleflex for about €760 million (approximately $795 million). Rumors began swirling late last year that Teleflex had interest in the business at the German medtech company. They now target a close of the deal in the third quarter of 2025.
Biotronik said the move reflects its commitment to active implantable devices. The VI business, meanwhile, features products like the Orsiro drug-eluting stent, Pantera Lux drug-coated balloon catheter, PK Papyrus stent and Freesolve resorbable magnesium scaffold.
“We are incredibly proud of the transformative contributions our Vascular Intervention division has made to interventional therapies and patient care worldwide,” said Dr. Alexander Uhl, CEO of Biotronik Group. “As healthcare continues to rapidly evolve, our focus is firmly on advancing AI-driven technologies that meet the needs of both patients and clinicians in the years to come. This strategic shift empowers us to amplify our investments in emerging technologies across cardiac rhythm management, patient monitoring, heart failure, and neuromodulation therapies. We will transform the future of healthcare innovation in these critical areas.”
Commentary on the deal with Biotronik from the Teleflex side
Teleflex said the acquisition reflects its commitment to investing in the interventional cardiology and peripheral vascular market.
Liam Kelly, Teleflex chair, president and CEO said in a news release that the acquired business is “robust research and development, clinical expertise, and global manufacturing capabilities.” Kelly believes the deal further bolsters Teleflex’s innovation pipeline and positions it to participate in the emerging potential for resorbable scaffold technologies.
Kelly said Teleflex considers the acquired business “a meaningful contributor to our growth in the coming years.”
“We are excited to announce the acquisition of Biotronik’s Vascular Intervention business, which we anticipate will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care,” said Kelly. “We believe the acquisition will allow us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market. In particular, the acquired coronary products will be highly complementary to our well-established complex percutaneous coronary intervention (PCI) platform and expand and enhance the legacy Interventional salesforce and offerings by combining existing Teleflex access products with the Vascular Intervention therapeutic devices.”
